AhR ligands in necrotizing enterocolitis: a provisional evidence map of ligand-specific biology and translational considerations.
- 1Université Paris Cité, Inserm, FPRM, Faculté de Pharmacie de Paris, Paris, France.
- 2FHU Prem'IMPACT Perinatal inflammation and prematurity, Paris, France.
Abstract
Necrotizing enterocolitis (NEC) remains a major cause of gastrointestinal morbidity and mortality in preterm infants, with no targeted mechanism-based therapy. Aryl hydrocarbon receptor (AhR) signaling is an emerging host-microbe interface because it integrates dietary, microbial, milk-derived, and host-derived ligands that regulate intestinal inflammation, epithelial homeostasis, and barrier integrity. Direct NEC-specific evidence for individual AhR ligands, however, remains sparse and uneven. This focused review maps direct NEC intervention evidence, independent replication, human NEC association or ex vivo evidence, AhR dependency, compartment specificity, mechanistic resolution, and translational considerations. Indole-3-carbinol (I3C), the synthetic agonist A18, and 3-indoleacrylic acid (IA) have direct intervention evidence in experimental NEC models. Two independent NEC studies support I3C, although the implicated cellular compartment differs between models. A18 provides direct protection in an experimental NEC model, activates AhR, and exhibits anti-inflammatory effects in human intestinal explants. However, it has not been independently replicated. IA is currently the most comprehensively characterized microbiota-derived ligand in NEC models. However, its mechanistic evidence predominantly comes from one recent study and awaits independent replication. Indole-3-lactic acid, indole-3-acetic acid, and indole-3-sulfate remain physiologically relevant candidates, supported by immature intestinal, human milk, or neonatal metabolic studies. Overall, current evidence supports a ligand-specific view of AhR biology in NEC while highlighting major gaps in replication, human validation, and translational studies.
Related
- Necrotizing Enterocolitis Secondary to Congenital Syphilis in an 18-Day-Old Neonate: Successful Treatment With Intravenous Penicillin.
- Advances in fecal biomarkers for necrotizing enterocolitis
- From sepsis to necrotizing enterocolitis with appendiceal perforation: a case report of successful salvage therapy with aztreonam–avibactam in an extremely preterm infant with NDM-producing Klebsiella pneumoniae
- β-glucan mitigates necrotizing enterocolitis-induced long-term cognitive impairment by remodeling gut microbiota and restoring tryptophan metabolite IAA-mediated gut–brain signaling
- Multicenter cohort of necrotizing enterocolitis in Latin America: evaluation of risk factors and clinical outcomes in Chilean Hospitals.
BibTeX
@article{ferraris2026ligands,
title = {{AhR ligands in necrotizing enterocolitis: a provisional evidence map of ligand-specific biology and translational considerations.}},
author = {Laurent Ferraris and Ioana Ferecatu and Julio Aires},
journal = {Gut microbes},
year = {2026},
month = oct,
doi = {10.1080/19490976.2026.2743958},
url = {https://europepmc.org/article/MED/42912465},
note = {CC BY},
}
RIS
TY - JOUR
TI - AhR ligands in necrotizing enterocolitis: a provisional evidence map of ligand-specific biology and translational considerations.
AU - Laurent Ferraris
AU - Ioana Ferecatu
AU - Julio Aires
PY - 2026
DA - 2026/10/23
JO - Gut microbes
DO - 10.1080/19490976.2026.2743958
UR - https://europepmc.org/article/MED/42912465
AB - Necrotizing enterocolitis (NEC) remains a major cause of gastrointestinal morbidity and mortality in preterm infants, with no targeted mechanism-based therapy. Aryl hydrocarbon receptor (AhR) signaling is an emerging host-microbe interface because it integrates dietary, microbial, milk-derived, and host-derived ligands that regulate intestinal inflammation, epithelial homeostasis, and barrier integrity. Direct NEC-specific evidence for individual AhR ligands, however, remains sparse and uneven. This focused review maps direct NEC intervention evidence, independent replication, human NEC association or ex vivo evidence, AhR dependency, compartment specificity, mechanistic resolution, and translational considerations. Indole-3-carbinol (I3C), the synthetic agonist A18, and 3-indoleacrylic acid (IA) have direct intervention evidence in experimental NEC models. Two independent NEC studies support I3C, although the implicated cellular compartment differs between models. A18 provides direct protection in an experimental NEC model, activates AhR, and exhibits anti-inflammatory effects in human intestinal explants. However, it has not been independently replicated. IA is currently the most comprehensively characterized microbiota-derived ligand in NEC models. However, its mechanistic evidence predominantly comes from one recent study and awaits independent replication. Indole-3-lactic acid, indole-3-acetic acid, and indole-3-sulfate remain physiologically relevant candidates, supported by immature intestinal, human milk, or neonatal metabolic studies. Overall, current evidence supports a ligand-specific view of AhR biology in NEC while highlighting major gaps in replication, human validation, and translational studies.
SN - 1949-0976
SN - 1949-0984
ER -